Bone Metabolism in Breast Cancer

We conducted a prospective study including 14 patients diagnosed with breast cancer confirmed by histology and 10 HVs as controls. Inclusion criteria was women with advanced invasive ductal breast carcinoma (stage III), according to the TNM classification system of the International Union Against Cancer. Exclusion criteria were neoadjuvant therapies and previous breast tumor surgery, another primary tumor development, presence of BM and/or bone metastasis and osteoporosis, as well as metabolic bone disease, such as vitamin D deficiency, thyroid disease, parathyroid disease or kidney damage. All BCP tumors were classified as Luminal A [estrogen receptor (ER) +, progesterone receptor (PR) +, epidermal growth factor receptor (HER2/neu (-)]. In addition, the patients were in menopause with an age range from 50 to 65 years old. Inclusion criteria for the HV group was to be a female donor for bone marrow transplant in menopause and exclusion criteria were female donors with osteoporosis, or metabolic bone disease, such as vitamin D deficiency, thyroid disease, parathyroid disease or kidney damage. HV had an age range between 45–65 years old. All individuals gave consent to participate in this study, which was performed in accordance with the principles of the Helsinki Declaration. IBYME-Ethical Committee approved this investigation and informed consent.